Citations

Showing 10 of 108083 citations.

Immune-Mediated Autonomic Neuropathies following Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia
Mangaonkar, Abhishek A. , Khateeb, Hassan Al, Duma, Narjust , Louis, Erik K. St. , Patnaik, Mrinal M. , Litzow, Mark R. , Kourelis, Taxiarchis , Mangaonkar, Abhishek A. , St Louis, Erik K, Hogan, William, St Louis, E K , McKeon, Andrew , Hogan, William J.

Mayo Clinic

Case Reports in Hematology | August 27, 2017 | Volume: 2017 | Issue: No issue available | Pages: 1-4

10.1155/2017/6803804 | PMID 28928996 Get It

Background/Aims. Autonomic dysfunction (AD) after allogeneic stem cell transplant (SCT) is a rare occurrence and likely immune-mediated in etiology. There is limited literature on this topic and hence, we wish to briefly describe management of two cases at our institution and their outcomes. Methods. We retrospectively identified two patients with immune-mediated AD after SCT from our database. Immune-mediated AD was defined as AD secondary to an immune-mediated etiology without an alternative cause and responding to immunosuppression. Results. The first case is of a 32-year-old man with acute myeloid leukemia (AML) who underwent double umbilical cord allogeneic SCT. The second patient was a 51-year-old woman with secondary AML who underwent matched-related donor allogeneic SCT. Both underwent an extensive work-up for an underlying etiology prior to treatment with intravenous immunoglobulin (IVIG). Conclusions. AD after SCT is a rare yet significant clinical entity. A work-up of underlying etiology should be performed. IVIG is a treatment option for these patients.
Change in Anterior Cruciate Ligament Graft Choice and Outcomes Over Time
Kaeding, Christopher C. , Pedroza, Angela , Reinke, Emily K. , Huston, Laura J. , Hewett, Timothy E. , Flanigan, David C. , Group, MOON Knee, Brophy, Robert H. , Wolf, Brian R. , Jones, Morgan H. , McCarty, Eric C. , Brophy, Robert H. , Jones, Morgan H , Group, MOON knee, Spindler, Kurt P , McCarty, Eric C

Mayo Clinic

Arthroscopy | August 26, 2017 | Volume: 33 | Issue: 11 | Pages: 2007-2014

10.1016/j.arthro.2017.06.019 | PMID 28847572 Get It

Purpose To analyze failure rate in 2‐year increments to determine if graft choice changed over time and graft failure rate. Methods A prospective 2002‐2008 database was used to identify risk factors for anterior cruciate ligament (ACL) retear. Subjects who had primary ACL retear with no history of contralateral surgery and 2‐year follow‐up were included. Subjects who underwent a multiligament reconstruction were excluded. Graft type, age, sex, smoking status, body mass index, Marx activity level at index surgery, medial and lateral meniscus status at time of ACL retear, sport played after ACL reconstruction, and clinical site were evaluated. Analysis was repeated using 2002‐2003 (early) and 2007‐2008 (late) 2‐year databases. Analysis of variance with post hoc analysis was performed to detect significant differences in age and Marx score by graft type over time. Results Two‐year follow‐up for graft failure was obtained on 2,497 of 2,692 (93%) subjects. There were 112 of 2,497 (4.5%) ACL retears identified at 2‐year follow‐up. The only predictor that changed between early/late periods was allograft use. Allograft odds ratio decreased from 13.1 to 9.5 ( P < .01). Allografts were used in older patients (31‐40 years) and with lower Marx scores (10‐8) from early to late periods. The mean age of subjects who received bone–patellar tendon–bone autografts did not significantly change over time (22.8‐23.5). The mean age of subjects who received hamstring autografts fell (27.9‐25.5). The mean age of subjects who received allografts rose significantly (31.3‐39.8, P < .01). The mean Marx score of subjects who received bone–patellar tendon–bone and hamstring autografts did not significantly change over time. The mean Marx score of subjects who received allografts decreased significantly ( P < .01). Conclusions After early recognition, allograft use in young active patients was a risk factor for retear; graft choice by surgeons changed in the late period to use of allografts in older and less‐active patients, which correlated with a significant decrease in retear risk. Level of Evidence Level III, case control study.
Considering health equity when moving from evidence-based guideline recommendations to implementation: a case study from an upper-middle income country on the GRADE approach
Eslava‐Schmalbach, Javier , Mosquera, Paola A. , Álzate, Juan Pablo , Jull, Janet , Katikireddi, Srinivasa Vittal , Morton, Rachel L, Thabane, Lehana , Shea, Bev , Singh, Jasvinder A. , Flórez, Iván D. , Schünemann, Holger J. , Singh, Jasvinder, Singh, Jasvinder A , Schünemann, Holger J , Thabane, Lehana , Pottie, Kevin , Welch, Vivian Andrea , Akl, Elie A. , Lang, Eddy , Stein, Aírton Tetelbom , Guyatt, Gordon , Tugwell, Peter

Mayo Clinic

Health Policy and Planning | August 26, 2017 | Volume: 32 | Issue: 10 | Pages: 1484-1490

10.1093/heapol/czx126 | PMID 29029068 Get It

Brain calcification in a CSF1R mutation carrier precedes white matter degeneration
Broderick, Daniel F. , Wszołek, Zbigniew K. , Konno, Takuya , Wszolek, Z.K.

Mayo Clinic

Movement Disorders | August 26, 2017 | Volume: 32 | Issue: 10 | Pages: 1493-1495

10.1002/mds.27130 | PMID 28843019 Get It

Clinicopathologic discrepancies in a population‐based incidence study of parkinsonism in olmsted county: 1991‐2010
Turcano, Pierpaolo , Mielke, Michelle M. , Josephs, Keith A. , Bower, James H., Parisi, Joseph E. , Savica, Rodolfo , Mielke, Michelle M , Boeve, Bradley F.

Mayo Clinic

Movement Disorders | August 26, 2017 | Volume: 32 | Issue: 10 | Pages: 1439-1446

10.1002/mds.27125 | PMID 28843020 Get It

ABSTRACTObjective: The purpose of this study was to examine the discrepancies between the clinical diagnosis of parkinsonism and neuropathological findings in a population‐based cohort with parkinsonian disorders.Background: The specific clinical diagnosis of parkinsonism is challenging, and definite confirmation requires neuropathological evaluation. Currently, autopsies are seldom performed, and most brain autopsies represent atypical or diagnostically unresolved cases.Methods: We used a defined population‐based incidence cohort with clinical parkinsonism (n = 669) from the Rochester Epidemiology Project in Olmsted County, Minnesota, 1991‐2010. We reviewed reports of all patients who underwent neuropathologic examination at autopsy (n = 60; 9%) and applied consensus pathologic guidelines for neurodegenerative disease diagnosis.Results: Among the 60 patients examined pathologically, the median time from the last recorded clinical diagnosis to death was 7 years (range from 2 to 17 years). Clinical–pathological concordance was found in 52 cases (86.7%), whereas 8 (13.3%) had a clinical‐pathological discrepancy. Four patients with a clinical diagnosis of idiopathic Parkinson's disease had no pathological evidence of Lewy bodies or α‐synucleinopathy; of these, pathological diagnoses were Alzheimer's disease (2 cases), progressive supranuclear palsy (1 case), and vascular parkinsonism (1 case). Two patients with clinical diagnoses of "dementia with Lewy bodies" and one patient with an "unspecified parkinsonism" had a pathological diagnosis of Alzheimer's disease without concomitant α‐synuclein lesions. One patient with clinically diagnosed "progressive supranuclear palsy" had indeterminate pathological findings without α‐synuclein or Aβ‐ or tau‐immunoreactive lesions at autopsy.Conclusions: Overall, the clinical diagnoses of parkinsonian subtypes had good concordance with pathological confirmation (86.7%). However, clinical–pathological discrepancies were documented in 13.3%. © 2017 International Parkinson and Movement Disorder Society
Incidence of Previously Undiagnosed Atrial Fibrillation Using Insertable Cardiac Monitors in a High-Risk Population
Reiffel, James A. , Kowey, Peter R. , Halperin, Jonathan L. , Wachter, Rolf , Pouliot, Erika , Ziegler, Paul , Investigators, for the REVEAL AF, Verma, Atul , Gersh, Bernard J. , Investigators, for the REVEAL AF

Mayo Clinic

JAMA Cardiology | August 26, 2017 | Volume: 2 | Issue: 10 | Pages: 1120

10.1001/jamacardio.2017.3180 | PMID 28842973 Get It

Neurotization of the Superficial Sensory Branch of Ulnar Nerve by the Distal Posterior Interosseous Nerve: Cadaveric Feasibility Study
Decaestecker, Laurent, Delclaux, Stépahnie, Aprédoaei, C., Tibbo, Meagan E. , Courtade-Saïdi, Monique , Mansat, Pierre , Laumonerie, Pierre , Laumonerie, Pierre

Mayo Clinic

Journal of Reconstructive Microsurgery | August 25, 2017 | Volume: 33 | Issue: 09 | Pages: 636-640

10.1055/s-0037-1605365 | PMID 28841737 Get It

Background In 2014, Delclaux et al described a case wherein the Battiston and Lanzetta's technique, modified by utilization of the posterior interosseus nerve (PIN), was used to perform double neurotization of the ulnar nerve (UN). This study evaluates the feasibility of transfer of proprioceptive fascicles of the PIN to the superficial sensory branch of the UN (SSBUN). Methods The surgeries were performed on 16 fresh cadaveric wrist specimens. PIN transfer was performed through the interosseous membrane and sutured to the SSBUN. The diameter for each nerve, number of fascicles, and the percentage of fascicles without axons, under ×10, ×40, and ×100 magnifications were performed by two observers. Results Neurotization of the SSBUN by the PIN was successful in all cases. The median diameter of the SSBUN and PIN was 3.5 (3–4) and 2.3 mm (1.6–3), respectively. The SSBUN contained 5.5 fascicles (4–7), while the PIN contained 2 fascicles (0–4). The 16 PIN had limited (10 cases) or no axonal reserve (6 cases). Conclusion This study supports the surgical and anatomical feasibility of neurotization of the SSBUN by the PIN. However, the PIN's limited axonal reserve may partially or totally compromise recovery.
Faculty Opinions recommendation of Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist.
Coddington, Charles C.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 25, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.728684802.793535623 Get It

Rationale and design of the Drug‐Eluting Stents vs Bare‐Metal Stents in Saphenous Vein Graft Angioplasty (DIVA) Trial
Brilakis, Emmanouil S. , Edson, Robert , Shunk, Kendrick , Goldman, Steven , Holmes, David R. , Bhatt, Deepak L. , Smith, Mark W. , Sather, Mike R., Colling, Cindy, Kar, Biswajit , Nielsen, Lori, Conner, T., Wagner, Todd H. , Rangan, Bavana V. , Ventura, Beverly, Lü, Ying , Holodniy, Mark , Shih, Mei‐Chiung, Brilakis, Emmanouil S , Bhatt, Deepak L , Lu, Ying , Banerjee, Subhash , Rao, Sunil V.

Mayo Clinic

Clinical Cardiology | August 25, 2017 | Volume: 40 | Issue: 11 | Pages: 946-954

10.1002/clc.22763 | PMID 28841230 Get It

VA Cooperative Studies Program #571 (DIVA) was designed to evaluate the efficacy of drug‐eluting stents (DES) for reducing aortocoronary saphenous vein bypass graft (SVG) failure when compared with bare‐metal stents (BMS) in participants undergoing stenting of de novo SVG lesions. Participants undergoing clinically indicated stenting of de novo SVG lesions were randomized in a 1:1 ratio to DES or BMS. Randomization was stratified by presence/absence of diabetes mellitus and the number of target SVG lesions (1 vs ≥2) within each participating site. At sites that did not routinely administer 12‐months of dual antiplatelet therapy after SVG stenting participants without acute coronary syndromes received 1 month of open‐label clopidogrel, followed by 11 months of clopidogrel for those assigned to DES and 11 months of placebo for those assigned to BMS. The primary endpoint was the 12‐month incidence of target‐vessel failure (defined as the composite of cardiac death, target‐vessel myocardial infarction, or target‐vessel revascularization). Secondary endpoints included the incidence of other clinical endpoints and the incremental cost‐effectiveness of DES relative to BMS. Due to lower‐than‐anticipated target‐vessel failure rates, target enrollment was increased from 519 to 762. The study had randomized 599 participants when recruitment ended in December 2015. The DIVA trial will provide clarity on the appropriate stent type for de novo SVG lesions.